The establishing of the first cancer models created a new perspective on the identification
and evaluation of new anti-cancer therapies in preclinical studies. Patient-derived xenograft …

Various preclinical models have been developed to clarify the pathophysiology of prostate
cancer (PCa). Traditional PCa cell lines from clinical metastatic lesions, as exemplified by …

The microbiota comprises the microorganisms that live in close contact with the host, with
mutual benefit for both counterparts. The contribution of the gut microbiota to the emergence …

Epigenetic processes govern prostate cancer (PCa) biology, as evidenced by the
dependency of PCa cells on the androgen receptor (AR), a prostate master transcription …

Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease with
diverse drivers of disease progression and mechanisms of therapeutic resistance. We …

Prostate cancers (PCs) with loss of the potent tumor suppressors TP53 and RB1 exhibit poor
outcomes. TP53 and RB1 also influence cell plasticity and are frequently lost in PCs with …

Lineage plasticity has emerged as an important mechanism of treatment resistance in
prostate cancer. Treatment-refractory prostate cancers are increasingly associated with loss …

HOXB13, a homeodomain transcription factor, critically regulates androgen receptor (AR)
activities and androgen-dependent prostate cancer (PCa) growth. However, its functions in …

Ferroptosis is a type of programmed cell death induced by the accumulation of lipid
peroxidation and lipid reactive oxygen species in cells. It has been recently demonstrated …

Abstract c-MYC (MYC) is a major driver of prostate cancer tumorigenesis and progression.
Although MYC is overexpressed in both early and metastatic disease and associated with …